Adcirca is a phosphodiesterase 5 inhibitor
(PDE5i) indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise ability.
Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model.
A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with a-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.
Phosphodiesterase 5 inhibitor
profiles against all human phosphodiesterase families: implications for use as pharmacological tools.
ICOS and partner Eli Lilly and Company are jointly developing IC351, a phosphodiesterase 5 inhibitor
for the treatment of erectile dysfunction.
In a 44 patient overseas study assessing the safety and efficacy (erectile response) of IC351 (the Company's phosphodiesterase 5 inhibitor
for the treatment of erectile dysfunction), IC351-treated patients showed significant improvement relative to placebo-treated patients in the primary endpoint (p<0.
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors
alone or in combination with [alpha]-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Treatment of phosphodiesterase 5 inhibitors
shows insufficient effectiveness in the treatment of post-prostatectomy ED and it is believed that the transplantation of stem cells cultivated on the surface of nanofibrous meshes can promote cavernous neuronal regeneration and repair erectile dysfunction.
Food and Drug Administration (FDA) has ordered labeling changes for erectile-dysfunction (ED) medications known as phosphodiesterase 5 inhibitors
to reflect a potential risk of sudden hearing loss associated with using the drugs.